Company intelligence / Profile preview

AiBtl BioPharma

Delaware, USA

Ownership: Private
Development stage: Other

Overview

Two lead all-natural, botanical-based CNS drugs (ABV-1505 for ADHD and ABV-1504 for MDD) are in Phase 2 trials with patent protection until 2040; the company claims promising safety/efficacy and is developing AI health-tech solutions for trial and patient optimization.

Therapeutic areas: Psychiatry
Modalities: Small moleculeNatural productBotanical drug
Industry: Biotech

Partnerships

Collaborations with health tech start-upsPartnerships with premier medical research institutions

Beyond the preview

Go deeper on AiBtl BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AiBtl BioPharma.

Explore the full profile